Deficiency of plasma ADAMTS13 activity could result in an accumulation of newly released ultra large (UL) VWF on endothelial cells where it is synthesized [5] and in blood [6], leading to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP). Here, VWF is linked to thrombotic thrombocytopenic purpura.